Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Adding cisplatin to gemcitabine improves treatment of advanced pancreatic carcinoma

The combination of cisplatin and gemcitabine improves the outcome in patients with locally advanced and/or metastatic adenocarcinoma of the pancreas, compared to gemcitabine alone, claims a team from Italy.

News image

fiogf49gjkf04

The researchers conducted a Phase III trial to compare gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma.

They published their results in the 15 February issue of Cancer.

Time to disease progression and the clinical benefit rate were determined.

The objective response rate, overall survival rate, and toxicity patterns of patients in the two treatment arms were evaluated as secondary end points

A total of 107 patients were randomized to receive gemcitabine (Arm A, n = 54) or a combination of gemcitabine and cisplatin (Arm B, n = 53).

In Arm A, a dose of 1000 mg/m2 gemcitabine per week was administered for 7 consecutive weeks. After a 2-week rest, treatment was resumed on Days 1, 8, and 15, of a 28-day cycle for 2 cycles.

In Arm B, cisplatin was given at a dose of 25 mg/m2 per week, 1 hour before gemcitabine, at the same dose that was used in Arm A. On Day 22, only gemcitabine was administered.

Patients were restaged after the first 7 weeks of therapy, and then again after the other 2 cycles.

The median time to disease progression was found to be 8 weeks in Arm A, and 20 weeks in Arm B.

In Arm A, 1 complete response and 4 partial responses were recorded on the basis of an intent-to-treat analysis, with an overall response rate of 9%.

Response rate:
Gemcitabine alone: 9%
Gemcitabine plus cisplatin: 26%
Cancer

In Arm B, there were no complete responses, whereas 14 partial responses were achieved, with an overall response rate of 26%.

This difference in the overall response rates was statistically significant.

The researchers found that the tumor growth control rate (total number of patients who achieved complete responses, partial responses, and stable disease) was 43% in Arm A and 57% in Arm B.

A clinical benefit was observed in 21 of 43 patients (49%) in Arm A and in 20 of 38 patients (53%) in Arm B, without any significant difference.

The median overall survival was 20 weeks for patients in Arm A, and 30 weeks for patients in Arm B.

Toxicity was mild in both treatment arms, with no significant differences between the two groups. However, there was a statistically higher incidence of Grade 1-2 asthenia in Arm B.

Dr Giuseppe Colucci, of the Oncology Institute in Bari, said on behalf of the group, "The addition of cisplatin to gemcitabine significantly improved the median time to disease progression and the overall response rate, compared with gemcitabine alone.

"The clinical benefit rate was similar in both arms. However, the median overall survival rate was more favorable for Arm B, although the difference did not attain statistical significance."

"The combination of cisplatin and gemcitabine currently may be considered as an optimal treatment for patients with locally advanced and/or metastatic adenocarcinoma of the pancreas," it was concluded.

Cancer 2002; 94(4): 902-10
01 March 2002

Go to top of page Email this page Email this page to a colleague

 23 November 2017 
Distance travelling for rectal cancer outcomes
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us